NONMEM Users Network Archive

Hosted by Cognigen

[NMusers] New Milestone for Division of Pharmacometrics (DPM) at FDA

From: Wang, Yaning <>
Date: Wed, 16 Oct 2019 17:27:54 +0000

Dear Colleagues:

I would like to share a very important milestone for Division of Pharmacome=
trics (DPM) at FDA (
d-research-cder/division-pharmacometrics). Today, DPM is the largest divisi=
on (N=31) across all the review divisions within Office of Clinical Pharm=
acology at US FDA (OCP,

When I joined FDA in 2003, there were only four pharmacometric reviewers sc=
attered across three clinical pharmacology divisions (DCP1/2/3, back then t=
here were only 3 divisions within Office of Clinical Pharmacology and Bioph=
armaceutics, OCPB, which later changed to OCP). Over the years, the functio=
n of pharmacometrics was first centralized under Dr. Larry Lesko's (former =
OCPB and OCP Office Director) leadership and Dr. Bob Powell served as the f=
irst head of Pharmacometrics followed by Dr. Joga Gobburru and Dr. Vikram S=
inha. We grew from a Team to Pharmacometrics Staff and eventually Division =
of Pharmacometrics. The number of review teams also increased from 2 to the=
 current 7 (5 pharmacometric teams, 1 PBPK team and 1 cross-discipline QT t=
eam). We are proud of our achievements and, more importantly, appreciate th=
e accumulative efforts and hard work of our current and former colleagues b=
oth within and outside FDA, including you all. We will build upon the succe=
ss and move the field of pharmacometrics to the next level in the years to =


Yaning Wang, Ph.D.
Division of Pharmacometrics
Office of Clinical Pharmacology
Office of Translational Sciences
Center for Drug Evaluation and Research
Food and Drug Administration
Phone: 301-796-1624
Disclaimer: The contents of this message are mine personally and do not nec=
essarily reflect any position of the Government or the Food and Drug Admini=

Received on Wed Oct 16 2019 - 13:27:54 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: Once subscribed, you may contribute to the discussion by emailing: